Results 51 to 60 of about 28,888 (167)

Differential Impact of Pharmacokinetic and Pharmacodynamic Variability on Response to Combination Therapy

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Interindividual variability (IIV) in drug response complicates both fixed‐dose design and individualized therapy. Understanding how pharmacokinetic (PK) and pharmacodynamic (PD) processes jointly shape this variability is essential, particularly in combination therapy, where multiple interacting pathways influence outcomes. This study employed
Kuteesa R. Bisaso, Ronald Kadada Karyaburo, Jackson K. Mukonzo, Ene I. Ette   +3 more
wiley   +1 more source

Microparticles of Lamivudine—Poly-ε-Caprolactone Conjugate for Drug Delivery via Internalization by Macrophages

Molecules, 2019
The past decade may be considered as revolutionary in the research field focused on the physiological function of macrophages. Unknown subtypes of these cells involved in pathological mechanisms were described recently, and they are considered as ...
Tomasz Urbaniak, Daniela Machová, Olga Janoušková, Witold Musiał   +3 more
doaj   +1 more source

Temporal Association Between COVID‐19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 4, Page 517-526, August 2026.
In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi, Allison Carroll, Vy H. Nguyen, Megan Michta, Xuan Q. Zhang, Young‐Suk Lim, Raymond T. Chung   +6 more
wiley   +1 more source

Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study

Infection and Drug Resistance, 2019
Xiaoning Wu,1–3,* Jialing Zhou,1–3,* Wen Xie,4 Huiguo Ding,5 Xiaojuan Ou,1–3 Guofeng Chen,6 Anlin Ma,7 Xiaoyuan Xu,8 Hui Ma,9 Youqing Xu,10 Xiaoqing Liu,11 Tongtong Meng,1–3 Lin Wang,1–3 Yameng Sun,1–3 Bingqiong Wang,1&
Wu X, Zhou J, Xie W, Ding H, Ou X, Chen G, Ma A, Xu X, Ma H, Xu Y, Liu X, Meng T, Wang L, Sun Y, Wang B, Kong Y, Ma H, You H, Jia J   +18 more
doaj  

Hepatitis B genotype G and high frequency of lamivudine-resistance mutations among human immunodeficiencyvirus/hepatitis B virus co-infected patients in Brazil

Memorias do Instituto Oswaldo Cruz, 2010
In this study, we evaluated the hepatitis B virus (HBV) genotype distribution and HBV genomic mutations among a group of human immunodeficiency virus-HBV co-infected patients from an AIDS outpatient clinic in São Paulo.
Adriana Cristina da Silva, Ângela Maria Miranda Spina, Marcílio Figueiredo Lemos, Isabel Takano Oba, Cristina de Fátima Guastini, Michele Soares Gomes-Gouvêa, João Renato Rebello Pinho, Maria Cássia Jacintho Mendes-Correa   +7 more
doaj   +1 more source

Chemokines in Alzheimer's Disease: Early Defence, Late Damage and the Impact of Sex and Infection

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 2, August 2026.
ABSTRACT Chemokines constitute a versatile signalling network maintaining homeostasis and glia–neuron communication in the healthy brain but become progressively dysregulated during aging and Alzheimer's disease (AD). This review examines how chemokine systems transition from tightly regulated homeostatic signals to drivers of chronic neuroinflammation
Blanca I. Aldana, Kristine Freude
wiley   +1 more source

Patterns of hepatitis B virus infection in Brazilian human immunodeficiency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations

Memorias do Instituto Oswaldo Cruz, 2006
Hepatitis B virus (HBV) molecular profiles were determined for 44 patients who were infected with human immunodeficiency virus (HIV) type 1 and had antibodies to the hepatitis B core antigen (anti-HBc), with and without other HBV serological markers.
Michel VF Sucupira, Francisco CA Mello, Eneida A Santos, Christian Niel, Valeria C Rolla, Juçara Arabe, Selma A Gomes   +6 more
doaj   +1 more source

Real‐world clinical and laboratory changes after switching to two‐drug regimen in HIV‐suppressed individuals: 48 weeks and beyond

HIV Medicine, Volume 27, Issue 8, Page 1241-1252, August 2026.
Abstract Introduction Two‐drug regimens (2DRs) may reduce long‐term drug toxicities and drug‐drug interactions for people with HIV (PWH) on antiretroviral therapy (ART). This study evaluated clinical and laboratory outcomes in PWH who switched from standard ART to dolutegravir and lamivudine (DTG + 3TC) in real‐world settings.
Tommy Hing‐cheung Tang, Ruby Tsz‐shan Kwong, Phillip Chan, Kwok‐wai Lam, Helen Shuk‐ying Chan, Man‐yee Chu, Wilson Lam, Tak‐chiu Wu, Wai‐shing Leung, Sai‐kwong Yung, Wan‐man Ting, Annabel Kai‐tung Choy, Joe Lok‐fung Tung, Jason Ka‐wah Fong, Daniel Kai‐yeung Yeung, Man‐po Lee   +15 more
wiley   +1 more source

Abnormal coagulation profile in people living with HIV-AIDS on combined Antiretroviral Therapy: findings from a case-control study in the Ho municipality, Ghana

The Pan African Medical Journal, 2018
INTRODUCTION: Although combined Anti-Retroviral Therapy (cART) has improved the quality of life and survival in people living with HIV-AIDS (PLWHA), there have been reports of increased non-AIDS related co-morbidities such as coagulopathies.
Richard Kobina Dadzie Ephraim, James Elikem Ahadzie, Patrick Adu, Joseph Boachie, Hope Agbodzakey, Prince Adoba, Obed Cudjoe   +6 more
doaj   +1 more source

Prevention of HBV Mother‐To‐Child Transmission (MTCT) Using Targeted HBV Birth Dose, and Treatment of High Viral Load Pregnant Women in Uganda

Journal of Viral Hepatitis, Volume 33, Issue 8, August 2026.
ABSTRACT Hepatitis B virus (HBV) mother‐to‐child transmission (MTCT) remains a major challenge in Uganda, where 43% of births occur at home, and access to timely birth dose (BD) vaccination is limited. We evaluated the impact of combining universal three‐dose (3D) infant vaccination, targeted BD vaccination, and maternal antiviral treatment for high ...
Samantha Hall, Ponsiano Ocama, Danielle Leavelle, Julius Kiwanuka, Brian Lwanga, Joan Nankya‐Mutyoba, Calvin Q. Pan, Christine Namulindwa, Viola Kasone, Rachel Beyagira, Homie Razavi   +10 more
wiley   +1 more source